An experimental vaccine against respiratory syncytial virus (RSV), one of the leading causes of infectious disease deaths in infants, has shown early promise in a Phase 1 human clinical trial. A team of researchers, including ...
Aug 01, 2019
0
337
Respiratory syncytial virus, a major cause of lower respiratory tract infections, is behind one of every four deaths from acute illness for children under 2 years old in Nicaragua, according to a new University of Michigan ...
Aug 01, 2019
0
4
Scientists at Duke University have identified one kind of lung cell that can hustle to repair its damaged DNA and survive an attack of the influenza A virus while other kinds of cells around it die in droves.
Jul 29, 2019
0
84
Respiratory syncytial virus (RSV) and other viruses now appear to be the main causes of severe childhood pneumonia in low- and middle-income countries, highlighting the need for vaccines against these pathogens, according ...
Jun 27, 2019
0
0
One of the most successful interventions in reducing infectious disease worldwide, vaccination still has limited effectiveness in protecting one group of patients—newborn infants. Now a study based at the Ragon Institute ...
Jun 13, 2019
0
121
A unique adjuvant, a substance that enhances the body's immune response to toxins and foreign matter, can prevent vaccine-enhanced respiratory disease, a sickness that has posed a major hurdle in vaccine development for respiratory ...
Jun 13, 2019
0
5
Antibodies are currently in use to treat diseases that range from cancer to autoimmunity and are usually administered to patients in multiple doses, much like medical drugs. However, the production and storage of antibodies ...
In healthy adults, RSV, or respiratory syncytial virus, feels like the common cold with a runny nose, chest congestion and cough. However, it is the second leading cause of death in infants. In fact, nearly 40 percent of ...
Mar 26, 2019
0
2
It's common knowledge that congested public places such as transit systems and airports harbor all kinds of potentially harmful microbes that pass easily from person to person. What's not clear is which infectious agents ...
Feb 20, 2019
0
3
Skin vaccination using a microneedle patch that contains the inactivated respiratory syncytial virus (RSV) and a compound that stimulates immune responses to the virus has been found to enhance protection against this serious ...
Dec 17, 2018
0
0
Human respiratory syncytial virus (RSV) causes respiratory tract infections. It is the major cause of lower respiratory tract infection and hospital visits during infancy and childhood. There is no vaccine, and the only treatment is oxygen.
In temperate climates there is an annual epidemic during the winter months. In tropical climates, infection is most common during the rainy season.
In the United States, 60% of infants are infected during their first RSV season, and nearly all children will have been infected with the virus by 2-3 years of age. Natural infection with RSV does not induce protective immunity, and thus people can be infected multiple times. Sometimes an infant can become symptomatically infected more than once even within a single RSV season. Severe RSV infections have increasingly been found among elderly patients.
RSV is a negative-sense, single-stranded RNA virus of the family Paramyxoviridae, which includes common respiratory viruses such as those causing measles and mumps. RSV is a member of the paramyxovirus subfamily Pneumovirinae. Its name comes from the fact that F proteins on the surface of the virus cause the cell membranes on nearby cells to merge, forming syncytia.
This text uses material from Wikipedia, licensed under CC BY-SA
